Literature DB >> 24981792

Diagnostic timelines and delays in diagnosing amyotrophic lateral sclerosis (ALS).

Sabrina Paganoni1, Eric A Macklin, Alexandra Lee, Alyssa Murphy, Judith Chang, Amanda Zipf, Merit Cudkowicz, Nazem Atassi.   

Abstract

The objective of this study was to characterize the diagnostic timelines and their predictors in people with amyotrophic lateral sclerosis (ALS). Patients were identified through ALS billing codes. Time from presenting symptom to first doctor visit, first doctor visit to suspected ALS diagnosis, suspected to confirmed ALS diagnosis, and presenting symptom to confirmed ALS diagnosis (total diagnostic time) were collected. Regression models were used to analyze the predictors of diagnostic delay. Three hundred and four ALS patients were included in the analysis. Median total diagnostic time was 11.5 months. Diagnostic timelines were longer in patients with age > 60 years (p < 0.001), sporadic ALS (p = 0.043), and limb onset (p = 0.010). The presence of fasciculations, slurred speech, and lower extremity weakness when symptoms were first noted were independent predictors of shorter time to ALS diagnosis (p = 0.04, p = 0.02, and p = 0.04, respectively). About half of the patients (52%) received an alternative diagnosis and each patient saw an average of three different physicians before ALS diagnosis was confirmed. In conclusion, diagnostic timelines in ALS are long, and patients see many physicians and receive multiple alternative diagnoses before the diagnosis of ALS is confirmed. Older age, sporadic disease, and limb onset can delay ALS diagnosis.

Entities:  

Keywords:  Diagnosis; delay; predictor; timeline

Mesh:

Year:  2014        PMID: 24981792      PMCID: PMC4433003          DOI: 10.3109/21678421.2014.903974

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  13 in total

1.  ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis.

Authors:  A Chiò
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

2.  Diagnostic delay in amyotrophic lateral sclerosis: what scope for improvement?

Authors:  E Househam; M Swash
Journal:  J Neurol Sci       Date:  2000-11-01       Impact factor: 3.181

3.  Factors affecting the diagnostic delay in amyotrophic lateral sclerosis.

Authors:  Eleonora Cellura; Rossella Spataro; Alfonsa Claudia Taiello; Vincenzo La Bella
Journal:  Clin Neurol Neurosurg       Date:  2011-12-14       Impact factor: 1.876

4.  Misdiagnosis in patients with amyotrophic lateral sclerosis.

Authors:  J M Belsh; P L Schiffman
Journal:  Arch Intern Med       Date:  1990-11

5.  El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic lateral sclerosis" workshop contributors.

Authors:  B R Brooks
Journal:  J Neurol Sci       Date:  1994-07       Impact factor: 3.181

6.  Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study.

Authors:  Stefano Zoccolella; Ettore Beghi; Guerrino Palagano; Angela Fraddosio; Vito Samarelli; Paolo Lamberti; Vito Lepore; Luigi Serlenga; Giancarlo Logroscino
Journal:  J Neurol Sci       Date:  2006-08-22       Impact factor: 3.181

7.  The diagnostic interval in amyotrophic lateral sclerosis.

Authors:  Yasuo Iwasaki; Ken Ikeda; Yasumitsu Ichikawa; Osamu Igarashi; Masao Kinoshita
Journal:  Clin Neurol Neurosurg       Date:  2002-05       Impact factor: 1.876

8.  Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000.

Authors:  B J Traynor; M Alexander; B Corr; E Frost; O Hardiman
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-09       Impact factor: 10.154

Review 9.  Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  R G Miller; C E Jackson; E J Kasarskis; J D England; D Forshew; W Johnston; S Kalra; J S Katz; H Mitsumoto; J Rosenfeld; C Shoesmith; M J Strong; S C Woolley
Journal:  Neurology       Date:  2009-10-13       Impact factor: 9.910

10.  Timeliness of diagnosis in motor neurone disease: a population-based study.

Authors:  Colette Donaghy; Alison Dick; Orla Hardiman; Victor Patterson
Journal:  Ulster Med J       Date:  2008-01
View more
  49 in total

1.  Whole brain fiber-based comparison (FBC)-A tool for diffusion tensor imaging-based cohort studies.

Authors:  Gali Zimmerman-Moreno; Dafna Ben Bashat; Moran Artzi; Beatrice Nefussy; Vivian Drory; Orna Aizenstein; Hayit Greenspan
Journal:  Hum Brain Mapp       Date:  2015-10-31       Impact factor: 5.038

Review 2.  Stem cell treatments for amyotrophic lateral sclerosis: a critical overview of early phase trials.

Authors:  Stephen A Goutman; Masha G Savelieff; Stacey A Sakowski; Eva L Feldman
Journal:  Expert Opin Investig Drugs       Date:  2019-06-12       Impact factor: 6.206

Review 3.  MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis.

Authors:  Frank Cloutier; Alier Marrero; Colleen O'Connell; Pier Morin
Journal:  J Mol Neurosci       Date:  2014-11-30       Impact factor: 3.444

4.  Combined brain and spinal FDG PET allows differentiation between ALS and ALS mimics.

Authors:  Donatienne Van Weehaeghe; Martijn Devrome; Michel Koole; Koen Van Laere; Georg Schramm; Joke De Vocht; Wies Deckers; Kristof Baete; Philip Van Damme
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-04-20       Impact factor: 9.236

Review 5.  Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?

Authors:  Katharine A Nicholson; Merit E Cudkowicz; James D Berry
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

Review 6.  Neuroimaging as a New Diagnostic Modality in Amyotrophic Lateral Sclerosis.

Authors:  Esther Verstraete; Bradley R Foerster
Journal:  Neurotherapeutics       Date:  2015-04       Impact factor: 7.620

7.  Epidemiology of amyotrophic lateral sclerosis in Southern Germany.

Authors:  Angela Rosenbohm; Raphael S Peter; Siegfried Erhardt; Dorothée Lulé; Dietrich Rothenbacher; Albert C Ludolph; Gabriele Nagel
Journal:  J Neurol       Date:  2017-02-20       Impact factor: 4.849

Review 8.  Pathophysiological and diagnostic implications of cortical dysfunction in ALS.

Authors:  Nimeshan Geevasinga; Parvathi Menon; P Hande Özdinler; Matthew C Kiernan; Steve Vucic
Journal:  Nat Rev Neurol       Date:  2016-09-23       Impact factor: 42.937

Review 9.  Comprehensive rehabilitative care across the spectrum of amyotrophic lateral sclerosis.

Authors:  Sabrina Paganoni; Chafic Karam; Nanette Joyce; Richard Bedlack; Gregory T Carter
Journal:  NeuroRehabilitation       Date:  2015       Impact factor: 2.138

10.  Metabolite Profiling Reveals Predictive Biomarkers and the Absence of β-Methyl Amino-l-alanine in Plasma from Individuals Diagnosed with Amyotrophic Lateral Sclerosis.

Authors:  Michael S Bereman; Kaylie I Kirkwood; Tharani Sabaretnam; Sarah Furlong; Dominic B Rowe; Gilles J Guillemin; Allyson L Mellinger; David C Muddiman
Journal:  J Proteome Res       Date:  2020-06-02       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.